基于常规磁共振成像的影像组学特征可预测II级和III级胶质瘤中端粒酶逆转录酶启动子突变状态
本研究回顾性纳入83例病理确诊的低级别胶质瘤患者作为训练队列,并从癌症影像档案馆(TCIA)纳入33例作为独立验证队列,基于三维对比增强T1加权和T2加权图像提取影像组学特征,构建预测端粒酶逆转录酶(TERT)启动子突变状态的影像组学特征。肿瘤影像组学特征表现最佳,训练队列AUC为0.948(0.903-0.993),验证队列AUC为0.827(0.667-0.988);在IDH亚组中,肿瘤影像组学特征的AUC范围为0.750至0.940。结论认为基于MRI的影像组学特征可无创评估低级别胶质瘤的TERT启动子突变,且不受IDH状态影响,纳入瘤周区域未显著提高性能。
要点
- 肿瘤影像组学特征预测TERT启动子突变性能最佳,训练队列AUC 0.948,验证队列AUC 0.827。
- 在IDH亚组中,肿瘤影像组学特征的AUC范围为0.750至0.940。
- 纳入瘤周区域未显著提高影像组学特征的预测性能。
关键影像表现/征象
- 构建了三种影像组学特征:肿瘤影像组学特征、肿瘤加瘤周影像组学特征和融合影像组学特征,均表现出良好的准确性和平衡的敏感度与特异度。
- 肿瘤影像组学特征表现最佳,训练队列AUC为0.948(0.903-0.993),验证队列AUC为0.827(0.667-0.988)。
诊断标准与关键数值
- 肿瘤影像组学特征预测TERT启动子突变的AUC:训练队列0.948(0.903-0.993),验证队列0.827(0.667-0.988)。
- 在IDH亚组中,肿瘤影像组学特征的AUC范围为0.750至0.940。
临床应用与阅片要点
- 基于常规MRI的影像组学特征可用于无创评估低级别胶质瘤的TERT启动子突变状态,且不受IDH状态影响。
- 纳入瘤周区域未显著提高影像组学特征的预测性能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Telomerase reverse transcriptase (TERT) promoter mutation status is an important biomarker for the precision diagnosis and prognosis prediction of lower grade glioma (LGG). This study aimed to construct a radiomic signature to noninvasively predict the TERT promoter status in LGGs.
METHODS: Eighty-three local patients with pathology-confirmed LGG were retrospectively included as a training cohort, and 33 patients from The Cancer Imaging Archive (TCIA) were used as for independent validation. Three types of regions of interest (ROIs), which covered the tumor, peri-tumoral area, and tumor plus peri-tumoral area, were delineated on three-dimensional contrast-enhanced T1 (3D-CE-T1)-weighted and T2-weighted images. One hundred seven shape, first-order, and texture radiomic features from each modality under each ROI were extracted and selected through least absolute shrinkage and selection operator. Radiomic signatures were constructed with multiple classifiers and evaluated using receiver operating characteristic (ROC) analysis. The tumors were also stratified according to IDH status.
RESULTS: Three radiomic signatures, namely, tumoral radiomic signature, tumoral plus peri-tumoral radiomic signature, and fusion radiomic signature, were built, all of which exhibited good accuracy and balanced sensitivity and specificity. The tumoral signature displayed the best performance, with area under the ROC curves (AUC) of 0.948 (0.903-0.993) in the training cohort and 0.827 (0.667-0.988) in the validation cohort. In the IDH subgroups, the AUCs of the tumoral signature ranged from 0.750 to 0.940.
CONCLUSION: The MRI-based radiomic signature is reliable for noninvasive evaluation of TERT promoter mutations in LGG regardless of the IDH status. The inclusion of peri-tumoral area did not significantly improve the performance.
引用
- Jiang C, Kong Z, Zhang Y, et al. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Neuroradiology. 2020. PMID: 32239241. doi:10.1007/s00234-020-02392-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。